F/M Emerald Life Sciences Innovation (LFSC) ETF Holdings & Analysis
ETFOther
What LFSC does
The F/M Emerald Life Sciences Innovation ETF (LFSC) strategically invests in pioneering life science enterprises. Its core objective is to identify companies that are well-positioned for substantial long-term growth and the creation of significant value. As an actively managed fund, LFSC benefits from a highly specialized and experienced team dedicated to conducting in-depth research into complex life sciences firms. The fund primarily targets U.S. equity securities, selecting those that demonstrate strong growth potential. Specific criteria for inclusion involve a company's leadership in technological advancement, its capacity for market disruption, or its innovative application of artificial intelligence. The expansive field of life sciences, as defined by the fund, encompasses various sectors including biotechnology, pharmaceuticals, medical diagnostics and devices, healthcare services and technologies, and synthetic biology. Stock selection is guided by a rigorous and extensive 10-step research framework. This meticulous process incorporates: Reviews of publicly accessible and external third-party information. Comprehensive peer reviews. Development of detailed financial and valuation models. In-house research and surveys. Direct engagement and interviews with company management, industry and medical experts, and supply chain representatives. Robust internal collaboration among the investment team. While its primary focus is on domestic equities, the fund retains the flexibility to allocate up to 20% of its capital to foreign companies, provided they are listed and traded on a U.S. exchange.
Fund profile
Top holdings
| Holding | Weight | |
|---|---|---|
| Travere Therapeutics Inc | 8.66% | |
| Corcept Therapeutics Inc | 6.79% | |
| LivaNova PLC | 6.65% | |
| Spyre Therapeutics Inc | 6.53% | |
| Cogent Biosciences Inc | 6.40% | |
| Mirum Pharmaceuticals Inc | 4.35% | |
| Billiontoone Inc | 3.92% | |
| Guardant Health Inc | 3.87% | |
| Cytokinetics Inc | 3.52% | |
| United Therapeutics Corp | 3.31% |
Geographic allocation
| Other | — |
| United States | 93.35% |
| United Kingdom | 6.65% |
PortView Portfolio Insights
PortView analyzes how LFSC fits your actual portfolio — position weight, ETF overlap with your other funds, sector and geographic exposure, concentration, and how this fund contributes to your portfolio risk and return. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.
Analyze LFSC in PortView →Related securities
Related stocks
Frequently asked questions
- What does LFSC track?
- LFSC is the F/M Emerald Life Sciences Innovation ETF, a Other ETF.
- What is the expense ratio of LFSC?
- Expense ratio data for LFSC is shown on the page when available from our data provider.
- What are the largest holdings in LFSC?
- Top holdings include TVTX, CORT, LIVN, SYRE, COGT.
- How can PortView analyze LFSC overlap with other ETFs?
- PortView computes the holdings overlap between LFSC and the other ETFs and stocks you own, plus your combined sector and geographic exposure, so you can see true diversification.
The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.